Alaunos Therapeutics, Inc. (TCRT)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.13
- As of
Kresmion compiles this page from TCRT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Alaunos Therapeutics, Inc. (TCRT): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-23.
See the full TCRT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TCRT on one page. Preview it with sample data, then open it live with a free account.
Preview the TCRT dossierActive events for TCRT
- medium13F: new position
CITADEL ADVISORS LLC new position in TCRT
- mediumEarnings above estimates
Q2-2023: Beat consensus by 10.9% - EPS $-6 vs $-6.732 estimate
- mediumEarnings below estimates
Q3-2023: Missed consensus by 12.0% - EPS $-6 vs $-5.355 estimate
- mediumEarnings below estimates
Q4-2023: Missed consensus by 6.8% - EPS $-4.9 vs $-4.59 estimate
- mediumEarnings above estimates
Q1-2023: Beat consensus by 5.9% - EPS $-6 vs $-6.3755 estimate
FREE, NO ACCOUNT
Every event on TCRT, as it fires
You are seeing 5 of 8 events recorded on TCRT since 2026-06-03.
The five above landed across 3 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TCRT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 98973P309 · 2026Q2 | $27K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TCRT
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TCRT against its peers
TCRT's operating margin of -84500.0% ranks in the 6th percentile of 7 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | TCRT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 5000 USD | 568651 USD | 32 | 10 |
| Gross margin | n/a | 35.3% | n/a | 5 |
| Operating margin | -84500.0% | -631.0% | 6 | 7 |
| Net margin | -83520.0% | -682.5% | 6 | 8 |
| Return on equity | -194.0% | -138.6% | 45 | 18 |
Peers (21): XCUR, OSRH, LEXX, AIM, CNSP, APRE, IMRN, CURX, VSBC, MTVA, NIKI, CSCIF, SKYE, CMMB, VTGN, BOLT, ALZN, BGMS, BCLI, RVPH, ACXP. Left out: FBLG (no annual filing), ENVB (no annual filing), CUBT (no annual filing), ADAPY (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (TCRT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TCRT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TCRT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.